498 related articles for article (PubMed ID: 17042915)
21. Extracellular K+ is a prerequisite for the function and plasma membrane stability of HERG channels.
Massaeli H; Guo J; Xu J; Zhang S
Circ Res; 2010 Apr; 106(6):1072-82. PubMed ID: 20133899
[TBL] [Abstract][Full Text] [Related]
22. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
23. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
24. Protriptyline block of the human ether-à-go-go-related gene (HERG) K+ channel.
Jo SH; Hong HK; Chong SH; Choe H
Life Sci; 2008 Jan; 82(5-6):331-40. PubMed ID: 18191158
[TBL] [Abstract][Full Text] [Related]
25. Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil.
Johannesen L; Vicente J; Mason JW; Sanabria C; Waite-Labott K; Hong M; Guo P; Lin J; Sørensen JS; Galeotti L; Florian J; Ugander M; Stockbridge N; Strauss DG
Clin Pharmacol Ther; 2014 Nov; 96(5):549-58. PubMed ID: 25054430
[TBL] [Abstract][Full Text] [Related]
26. F463L increases the potential of dofetilide on human ether-a-go-go-related gene (hERG) channels.
Cheng G; Wu J; Han W; Sun C
Microsc Res Tech; 2018 Jun; 81(6):663-668. PubMed ID: 29573040
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block.
Rajamani S; Anderson CL; Anson BD; January CT
Circulation; 2002 Jun; 105(24):2830-5. PubMed ID: 12070109
[TBL] [Abstract][Full Text] [Related]
28. Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking.
Han S; Zhang Y; Chen Q; Duan Y; Zheng T; Hu X; Zhang Z; Zhang L
Eur J Pharmacol; 2011 Jan; 650(1):138-44. PubMed ID: 20951697
[TBL] [Abstract][Full Text] [Related]
29. Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.
Potet F; Lorinc AN; Chaigne S; Hopkins CR; Venkataraman R; Stepanovic SZ; Lewis LM; Days E; Sidorov VY; Engers DW; Zou B; Afshartous D; George AL; Campbell CM; Balser JR; Li M; Baudenbacher FJ; Lindsley CW; Weaver CD; Kupershmidt S
J Biol Chem; 2012 Nov; 287(47):39613-25. PubMed ID: 23033485
[TBL] [Abstract][Full Text] [Related]
30. Intracellular Binding of Terfenadine Competes with Its Access to Pancreatic ß-cell ATP-Sensitive K
Zünkler BJ; Wos-Maganga M; Bohnet S; Kleinau A; Manns D; Chatterjee S
J Membr Biol; 2023 Feb; 256(1):63-77. PubMed ID: 35763054
[TBL] [Abstract][Full Text] [Related]
31. A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels.
Lin C; Cvetanovic I; Ke X; Ranade V; Somberg J
Am J Ther; 2005; 12(4):328-36. PubMed ID: 16041196
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the effects of metoclopramide and domperidone on HERG channels.
Claassen S; Zünkler BJ
Pharmacology; 2005 Apr; 74(1):31-6. PubMed ID: 15640612
[TBL] [Abstract][Full Text] [Related]
33. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.
Katchman AN; Koerner J; Tosaka T; Woosley RL; Ebert SN
J Pharmacol Exp Ther; 2006 Mar; 316(3):1098-106. PubMed ID: 16278312
[TBL] [Abstract][Full Text] [Related]
34. Involvement of caveolin in low K+-induced endocytic degradation of cell-surface human ether-a-go-go-related gene (hERG) channels.
Massaeli H; Sun T; Li X; Shallow H; Wu J; Xu J; Li W; Hanson C; Guo J; Zhang S
J Biol Chem; 2010 Aug; 285(35):27259-27264. PubMed ID: 20605793
[TBL] [Abstract][Full Text] [Related]
35. Blockade of HERG cardiac K+ current by antifungal drug miconazole.
Kikuchi K; Nagatomo T; Abe H; Kawakami K; Duff HJ; Makielski JC; January CT; Nakashima Y
Br J Pharmacol; 2005 Mar; 144(6):840-8. PubMed ID: 15778703
[TBL] [Abstract][Full Text] [Related]
36. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
37. Structural determinants of HERG channel block by clofilium and ibutilide.
Perry M; de Groot MJ; Helliwell R; Leishman D; Tristani-Firouzi M; Sanguinetti MC; Mitcheson J
Mol Pharmacol; 2004 Aug; 66(2):240-9. PubMed ID: 15266014
[TBL] [Abstract][Full Text] [Related]
38. Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.
Ficker E; Jarolimek W; Brown AM
Mol Pharmacol; 2001 Dec; 60(6):1343-8. PubMed ID: 11723241
[TBL] [Abstract][Full Text] [Related]
39. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?
Weerapura M; Nattel S; Chartier D; Caballero R; Hébert TE
J Physiol; 2002 Apr; 540(Pt 1):15-27. PubMed ID: 11927665
[TBL] [Abstract][Full Text] [Related]
40. Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel.
Singleton DH; Boyd H; Steidl-Nichols JV; Deacon M; Groot MJ; Price D; Nettleton DO; Wallace NK; Troutman MD; Williams C; Boyd JG
J Med Chem; 2007 Jun; 50(13):2931-41. PubMed ID: 17536794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
